Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PepGen Inc. - Common Stock (NQ: PEPG )

12.44 +0.76 (+6.51%)
Streaming Delayed Price Updated: 11:22 AM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,303
Open 11.77
Bid (Size) 12.33 (2)
Ask (Size) 12.69 (1)
Prev. Close 11.68
Today's Range 11.77 - 12.71
52wk Range 3.720 - 17.51
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Insiders Buying GameStop And 2 Other Stocks
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. 
Via Benzinga

Performance

YTD
+75.46%
+75.46%
1 Month
-14.09%
-14.09%
3 Month
+71.59%
+71.59%
6 Month
+121.75%
+121.75%
1 Year
-12.82%
-12.82%

More News

Read More
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via GlobeNewswire
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
Via InvestorPlace
PepGen: Q3 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
From PepGen Inc.
Via GlobeNewswire
Over $37M Bet On This Industrial Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
From PepGen Inc.
Via GlobeNewswire
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
Via MarketBeat
Top 4 Health Care Stocks That May Crash This Quarter
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
From PepGen Inc.
Via GlobeNewswire
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
From PepGen Inc.
Via GlobeNewswire
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
From PepGen Inc.
Via GlobeNewswire
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
From PepGen Inc.
Via GlobeNewswire
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
From PepGen Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.